A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
Condition: Osteosarcoma
MeSH terms: Sarcoma; Osteosarcoma
Intervention: Cyclophosphamide and Sirolimus
Intervention description: The dose of cyclophosphamide will start at 200 mg (4 tablets) per day on day 1 and will be taken for 7 days every other week of a 28 day cycle.
Subjects will take 12 mg (12 tablets) of sirolimus on day 1 of treatment as a loading dose followed by 4 mg (4 tablets) daily continuously
Intervention MeSH terms: Sirolimus; Cyclophosphamide; Temsirolimus; MTOR Inhibitors
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Allocation: Non-Randomized
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 49.0
Sex: All
Minimum age: 16 Years
Healthy volunteers: No
Keywords: sarcoma; Cyclophosphamide; Sirolimus; Progressive or recurrent, advanced (unresectable or metastatic) high-grade osteosarcoma, Ewing's or soft tissue sarcoma previously treated with chemotherapy.

Summary:

      The purpose of this Phase II study will assess the effectiveness of the combination of oral
      cyclophosphamide and sirolimus in sarcoma patients with relapsed or widespread disease who
      cannot be cured by surgery, radiation or conventional chemotherapy.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Progressive or recurrent, advanced (unresectable or metastatic) high-grade
             osteosarcoma, Ewing's or soft tissue sarcoma previously treated with chemotherapy.

          -  Bi-dimensionally measurable lesion(s) on cross-sectional radiography, such as computed
             tomography or magnetic resonance imaging, within 2 weeks of enrollment.

          -  ECOG/Zubrod performance score 0, 1 or 2.

          -  Total WBC >3,000, neutrophil count >1,000, platelet count >100,000 within 2 weeks of
             enrollment.

          -  Serum creatinine <2.0 times the institutional upper limit of normal (IULN) within 2
             weeks of enrollment.

          -  AST and ALT <2.5 times IULN (or if liver involvement by sarcoma <5 times IULN) within
             2 weeks of enrollment.

          -  Able to ingest oral medications.

          -  Sexually active women and men of childbearing potential must agree to use an effective
             method of birth control during the course of the study and for up to 1 month following
             the last dose of the study drug, in a manner such that risk of pregnancy is minimized.
             Surgical sterilization, oral contraceptive pills, intrauterine device, double barrier
             (e.g. condom and diaphragm or spermicidal agents) or abstinence are acceptable forms
             of birth control.

          -  Women of childbearing potential must have a negative pregnancy test within 2 weeks
             prior to treatment.

          -  Patient must be >16 years of age at the time the consent document is signed by the
             patient.

          -  A paraffin block containing sarcoma, either from a previous surgery or recent biopsy,
             must be available for correlative studies. If a paraffin block containing sarcoma is
             not available, patients are required to undergo biopsy to obtain tissue for the
             correlative studies.

        Exclusion Criteria:

          -  Active infection requiring antibiotic treatment.

          -  Diabetes mellitus not under good control (e.g. hemoglobin A1c > 8% or fasting glucose
             > 180 mg/dl) with oral agents or insulin.

          -  Prior treatment with mTOR inhibitor for sarcoma.

          -  Less than 3 weeks from prior treatment with chemotherapy to start of treatment with
             cyclophosphamide and sirolimus. Toxicities from prior chemotherapy (except alopecia)
             should be grade 1 or less before starting treatment with cyclophosphamide and
             sirolimus.

          -  Prior radiation less than two weeks since the administration of the last fraction of
             radiation therapy to the start of treatment. Patients must have recovered from grade 2
             or higher radiation-associated toxicities to be eligible. All measurable lesions,
             which are being targeted, must be outside previously radiated fields or have
             documented progression at least 6 weeks after completion of radiation.

          -  Untreated or active CNS involvement by sarcoma.

          -  Active second malignancy other than carcinoma in situ. Patients with malignancy other
             than sarcoma in remission are eligible.

          -  Women who are pregnant or breastfeeding.